Screener
Iovance Biotherapeutics, Inc. IOVA Business Segments — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| (in thousands) | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Royalties | 2,250 | 1,229 | 4,901 | 2,555 |
| Total cost of sales | $43,595 | $48,881 | $86,093 | $91,595 |
| Expenses | ||||
| Research and development | $53,773 | $71,569 | $111,143 | $137,619 |
| General and administrative | 18,617 | 19,668 | 37,317 | 39,524 |
| Sales and marketing | 15,536 | 11,472 | 30,652 | 24,830 |
| Depreciation and amortization | 9,500 | 9,350 | 18,039 | 17,415 |
| Other segment items (b) | 5,607 | 10,670 | 13,859 | 26,114 |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s business segments — research and development expense?
- Iovance Biotherapeutics, Inc. (IOVA) reported business segments — research and development expense of $53.77M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s business segments — research and development expense changed year-over-year?
- Iovance Biotherapeutics, Inc.'s business segments — research and development expense decreased by 24.9% year-over-year, from $71.57M to $53.77M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s business segments — research and development expense?
- Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s business segments — research and development expense has grown at a -4.3% compound annual growth rate (CAGR), from $298.27M to $273.31M.
- What does business segments — research and development expense mean?
- This tracks the investment in clinical trials, laboratory research, and regulatory activities required to develop and advance the company's pipeline. For a biopharmaceutical firm, this is the primary driver of future growth and long-term value creation.
Ask your AI about Iovance Biotherapeutics, Inc.'s business segments — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude